公司资料
Trevi Therapeutics 股价、新闻与催化剂
- 股票代码:
- TRVI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
18.08 USD (+0.67%)
收盘价
最后更新: 2026年8月24日
1.92B USD
市值
股价为何变动
As of Aug 24, 2026, TRVI closed up 0.67% at $18.08. No new same-company headline was identified in the current news window.
公司概览
业务概览
Trevi Therapeutics is a neuroscience and cough-related company focused on chronic cough and severe pruritus biology. Its programs aim to address symptom burdens with targeted therapies.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Trevi sits in specialty biotechnology.
商业模式特征
The company depends on clinical validation, symptom-specific differentiation, and the ability to build a focused CNS/respiratory story.
生物医药行业定位
Trevi is a high-catalyst specialty name where clinical data can quickly reshape the investment case.
未来催化剂
- Trevi’s catalysts are Haduvio and the chronic-cough / pruritus opportunities, with the next clinical step deciding whether the asset can become a real franchise. The stock is still driven by proof that the mechanism works in patients.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。